Connect with us

Featured

Bitcoin Could Be Rescued By Milennials​

Daniel Chase

Published

on

stock_price_bitcoin

Everyone has a friend or loosely connected acquaintance they they wish would just give it a rest. I’m talking about those people that are so damned impassioned about a particular topic that they not only post regularly about it on social media but at every party, function, or event, it’s really all they can talk about. For one friend of mine in particular, he always talks about cryptocurrencies with statements akin to Will Hunting when he hit his stride in that Southie bar.

We try to tell him that Bitcoin has been struggling to get out of bed after a near two-year dry spell after enjoying an earth-shattering bull run in 2017. Sure, in the past bitcoin’s price shot up from mere pennies to nearly $20,000 in less than a year, but the once-famous crypto has failed time and time again to break out of its bear market tendencies. 

Nearly a decade has passed since Nakamoto released the fabled white paper describing the primordial framework of a peer-to-peer currency network. At the time, an anonymous cryptographer, with the pseudonym of Satoshi Nakamoto, was furious with the fact that consumers were slowly being falling prey to the inefficacies of banks and other financial institutions. 

Nakamoto wrote that “commerce on the internet [had] come to rely almost exclusively on financial institutions as trusted third parties to process electronic payments,” and this nurtured dependence would ultimately lead to a fiscal downturn. With a P2P currency network that kept records of every transaction, banks were no longer needed and the era of decentralized currency was on the rise. 

For a time, everyone wanted a piece of the cryptocurrency market, but that has all been reduced to whispers and murmurs. However, according to a recent survey, interest in bitcoin and cryptocurrencies may be on the rise once more, namely because millennials and younger generations don’t trust those dastardly traditional banking institutions. According to Forbes, 43% of millennial online traders “have more trust in crypto exchanges than the U.S. stock market, compared to 77% of Gen X respondents who have more trust in stock exchanges.” 

It would seem that millennials could actually get credit for contributing something of value to society other than complaining about presidents and student loans. 

“We’re seeing the beginning of a generational shift in trust from traditional stock exchanges to crypto exchanges. Younger investors’ experience with he stock market has seen a great deal of loss of trust, with the fall of Lehman Brothers because of irresponsible practices followed by the worst recession since the Great Depression…Trust further eroded when Americans saw how..banks get free money through quantitative easing while their cost living continues to rise…”

Guy Hirsch, U.S. managing director, eToro

The growing millennial mistrust of banking institutions could rescue bitcoin from its current crypto winter. It is interesting that we place such a large amount of trust in banks, storing thousands of dollars in their systems, and yet we have absolutely no idea what happens to our money when its “protected” in our accounts. The trust-based model of depending on banks to transact and safely store money is outdated and, if there’s anything that can be said about younger generations, it’s the idea that older technologies and systems can and should be replaced as soon as possible. 

According to CoinMarketCap, there are presently over 2,000 cryptocurrencies on the market but analysts say that a majority of these coins are virtually worthless. The initial coin offering explosion of 2017 catalyzed an industry replete with hot shot entrepreneurs ready to throw money at the first crypto they could get their hands on, without any idea as to if these coins functioned. 

“Almost every ICO was just an attempt to raise money but there was no use for the underlying token…The vast majority of what’s our there will be eliminated…”

Barry Silbert, CEO of Digital Currency Group 

Only time will tell as to whether the age of cryptocurrencies will rise once more, but if we are depending on millennial to come to the rescue, historically their collective followthrough is less than noteworthy. 

Continue Reading
Click to comment

Featured

Alibaba (BABA) Stock Price Signaling Buy Or Sell After The Recent Surge?

Joe Samuel

Published

on

technology stock price

China has grown into the world’s second-largest economy over the past few decades. One Chinese company that mirrors the remarkable growth of the country is Alibaba Group Holding Ltd – ADR (NYSE:BABA). The e-commerce behemoth is rightly called the ‘Amazon of China’ and it has grown at a remarkable pace over the past two decades.

Key Details

However, Jack Ma, who oversaw the company’s rise has decided to depart. Most analysts believe that Alibaba stock is still a buy despite this development. There are several factors to consider, however.

Jack Ma may have departed but the robust business model that he has created is still in place. That will likely continue to help drive the company’s growth. The Alibaba marketplace is massive and it allows Chinese companies to sell abroad, while at the same time allowing domestic consumers to sell to each other.

Sales Continue To Drive Margins

On mobile devices alone, the company recorded as many as 755 million monthly active users in China. On top of e-commerce, Alibaba has also branched into a tech company. It has its own cloud service known as Alibaba Cloud and has also created its own payments platform Alipay. Alipay already boasts of as many as 600 million users.

Moreover, despite trade tensions with the United States, the Chinese economy is expected to grow over the next decade and expand the size of the middle class. China is already the biggest market for e-commerce companies and the expanding middle class will continue to contribute towards its hyper-growth. Joseph Tsai, the company’s vice chairman stated that even smaller cities in China are expanding rapidly and that retail consumption would hit $7 trillion by 2030.

Last but not least, the company has consistently delivered impressive financial results and in the recent quarters, it has managed to beat analysts’ earnings estimates comfortably.

Continue Reading

Featured

Stock Price Newsletter – September 23, 2019

Jon Phillip

Published

on

biotech stock to watch 2019

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

The fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

See For Yourself, CLICK HERE


This Stock is Looking to Disrupt the Multi-Billion Dollar Defense Industry

Global spending on security solutions is projected to reach $7.4 billion in 2019 and increase to over $11.3 billion by 2025 with a CAGR of 8.2% and is forecast to see consistent growth for the next several years. What Could This Mean For ONE COMPANY?

Read More


Multi-Billion Dollar Markets Are Ready For A Shake-Up

There’s no denying that biotechnology is one of the hottest markets in the world. Right now a multi-billion-dollar segment is ready for a shakeup and one biotech stock could hold the secret to doing just that!

Continue Reading

Continue Reading

Biotechnology

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

Joe Samuel

Published

on

stock market today

Biotech has been one of the hottest sectors for investors for as long as it has existed and the reasons are self-evident. It is a sector that uses cutting edge technology and comes up with treatments for a wide range of diseases.

Moreover, the fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 19, PharmaCyte saw more than 6 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

What To Watch For

This week PharmaCyte (PMCB) will host a call designed to update all shareholders and the investment community simultaneously of material developments. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. FDA to treat locally advanced, inoperable pancreatic cancer. It will also cover developments related to PharmaCyte’s product pipeline. PharmaCyte has been working on these and will discuss things not yet reported in a press release.

Catalyst Pharmaceuticals (CPRX)

The first one to watch is Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). It is a small-cap stock engaged in developing medicines for rare diseases. Catalyst managed to get an approval for one of its products from the FDA earlier this year.

Since the approval of the Lambert-Eaton myasthenic syndrome (LEMS treating medicine Firdapse, Catalyst stock went on a massive rally from January to April. The approval of a rival drug halted the rally. Only after a civil suit from Catalyst did the stock stabilize somewhat.

Last week, Catalyst stock received a fresh boost after the company announced that it was going to make a secondary offering. However, the company decided to pull the offering the very next day and that affected the stock price once again.

What To Watch For

Analysts believe that pulling the secondary offering was the right long term decisions and this stock could be heading for another rally soon.

Eyepoint Pharmaceuticals (EYPT)

The biotech stock that could prove to be a major winner in the biotech sector this month is that of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT). There are two factors at play. The company revenues are going to rise significantly in the coming years due to the commercial launch of two medicines.

The first one is Yutiq, which is meant for the treatment of chronic non-infectious uveitis and the other one is Dexycu, which is meant for postoperative ocular inflammation.

What To Watch For

The company is currently trading at only double that of its future revenue and that is a very attractive multiple. EYPT stock has caught the attention of analysts on Wall Street. Guggenheim has set a 12-month target price of $4, which reflects 116% gains during the period.

stock market news today
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com